Lv1
80 积分 2021-01-31 加入
Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials
8个月前
已完结
[Chinese expert consensus on iruplinalkib for the treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer (2024 edition)]
8个月前
已完结
[China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)]
8个月前
已完结
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10个月前
已完结
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis
1年前
已完结
MET alterations in NSCLC—Current Perspectives and Future Challenges
1年前
已关闭
MET alterations in NSCLC—Current Perspectives and Future Challenges
1年前
已完结
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2年前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
2年前
已完结
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
2年前
已完结
皖公网安备34019202002308
